Clinical Trials in Subiaco, Western Australia
1 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled192 locationsNCT07195695
Recruiting
Phase 3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim416 enrolled162 locationsNCT06151574
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 1Phase 2
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Advanced Lung Cancer
BioNTech SE594 enrolled45 locationsNCT06892548
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 1
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.168 enrolled16 locationsNCT06022029
Recruiting
Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled41 locationsNCT04606446